Lumacaftor
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Lumacaftor: From Cystic Fibrosis to Leprosy
One-Sentence Summary
Lumacaftor is a CFTR corrector, originally used to treat cystic fibrosis in patients with the F508del mutation. The TxGNN model predicts a possible association with Leprosy, but this is a model-prediction-only signal — no clinical trials and no literature currently support this direction, and the underlying mechanistic rationale is itself assessed as weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cystic fibrosis (F508del CFTR mutation) — no formal Finland-approved indication text is on file |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 99.44% (rank 6001) |
| Evidence Level | L5 (model prediction only) |
| Finland Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is flagged as a data gap in the drug record. Based on the information available, lumacaftor is a CFTR corrector — it helps the misfolded F508del CFTR protein fold correctly and traffic to the cell membrane, and its established use is in cystic fibrosis.
Leprosy is caused by Mycobacterium leprae infection and its treatment relies on antimycobacterial activity or host immune modulation — mechanistically distinct domains from CFTR protein folding/trafficking. The evidence pack's own mechanistic assessment concludes there is no known overlap between the CFTR-correction pathway and antimycobacterial or immune-modulation pathways, and no shared molecular pathway or supporting indirect evidence was identified.
Because of this, the mechanistic link should be treated as speculative rather than mechanistically grounded, and it is consistent with the L5 (prediction-only) evidence level and the "Hold" recommendation below.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Lumacaftor is not marketed in Finland and has no marketing authorizations on file (0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score (L5), with no clinical trials, no literature, and a mechanistic rationale that the evidence pack itself assesses as weak/speculative. There is also a blocking data gap on Fimea/TFDA package insert warnings and contraindications, which prevents even a baseline (S1) safety review.
To proceed, the following is needed:
- TFDA/Fimea package insert data (warnings, contraindications) to clear the blocking data gap (DG001)
- Confirmed mechanism of action detail from DrugBank (DG002)
- Preclinical or mechanistic studies establishing a plausible link between CFTR correction and leprosy pathophysiology
- Any real-world, case-report, or exploratory clinical evidence before advancing beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.